Athira Pharma Inc. (ATHA) Issues 2022 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Athira Pharma Provides 2022 Pipeline Outlook
January 5, 2022 7:00 AM ESTTopline data from ACT-AD Phase 2 Alzheimers disease study in 2Q22
LIFT-AD Phase 3 Alzheimers disease study sample size increased to strengthen statistical power of co-key secondary endpoints and enhance the potential for a single pivotal clinical study
Milestones achieved with initiation of SHAPE Phase 2 Parkinsons disease dementia clinical trial and IND filing for ATH-1020
BOTHELL, Wash., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Athira Pharma,... More
